CLYR Health Tirzepatide Review

CLYR Health prices its GLP-1s better than anyone else in this comparison and sells them next to products that raise a different set of questions. Both facts belong in the same review. Our research (September 1, 2026) separates them.

Important: These Are Compounded Medications

"A GLP-1 receptor agonist compounded by a state-licensed 503A pharmacy. Combined with Vitamin B12 for energy and metabolic support. Once-weekly subcutaneous injection."

Compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or manufacturing quality. With the tirzepatide shortage resolved in October 2024 and semaglutide in early 2025, lawful 503A compounding now turns on a documented clinical reason for the individual patient. The B12 combination deserves a note. Adding vitamin B12 to compounded semaglutide is common in this market and is marketed for energy and to soften side effects; the evidence that it changes outcomes is weak. It also means the preparation is not a straight copy of an approved product — which is part of how compounders justify their position post-shortage. Understand it as a formulation choice with regulatory as well as clinical implications, not simply a bonus ingredient.

Priced by the Units You Actually Inject

This is genuinely the best pricing disclosure we have encountered. CLYR does not price by tier name or by "starting from"; it prices by the number of units on the syringe, and shows both the discounted cycle price and the cancel-anytime monthly price side by side. Semaglutide + B12: at 8 units/week (0.4mg), $130/month on an 8-week cycle ($259 billed once) or $169/month monthly. At 18 units/week (0.9mg), $160/month on cycle ($319) or $199/month monthly. At 30 units/week (1.5mg), $190/month on cycle ($379) or $229/month monthly. A 3-month titration program covering the climb from 8 to 18 to 30 units is $567 billed once, or $189/month. Tirzepatide + B12 (10mg/mL multi-dose vial): $149 for the first month at 20 units/week, then $199/month on 8-week cycles. Up to 40 units/week is $199/month on cycle ($398) or $249/month monthly. A flat 70 units/week is $329/month. At 90+ units/week, $349/month on cycle ($698), $333/month on a 3-month prepay ($999), or $399/month monthly.

"Priced by weekly dose. Pay for the vial you are actually on: $169, $199, or $229 a month."

Publishing a starter price that covers the whole titration climb — "One starter price covers your climb through the early doses, no mid-titration" increase — removes the most common billing surprise in this category. Shipping is free and priority, packaging is described as discreet and temperature-safe, and every tier is marked cancel anytime.

The Wider Catalogue

CLYR is not a GLP-1 practice. It describes itself as offering "doctor-prescribed weight loss with compounded GLP-1, plus longevity, sexual health, and protocol care," and the catalogue includes NAD+ injections from $109/month, a 3% GHK-Cu copper peptide cream at $179, PT-141 from $83/month, and several ED products. It also lists what it calls "2 antiparasitic protocols":

"Ivermectin 18mg 30-capsule $99 · Ivermectin + Mebendazole Broader coverage $139 · Ivermectin 30mg Higher strength $139"

Ivermectin and mebendazole are both legitimate, FDA-approved antiparasitic medicines with well-established indications, and there is nothing improper about a licensed provider prescribing either for a diagnosed parasitic infection. What is worth noticing is the framing. These are presented as consumer-selectable protocols tiered by "broader coverage" and "higher strength" — the way a supplement range is merchandised — rather than as treatments for a specified diagnosis. A 30-capsule course of ivermectin at a strength ladder, bought from a menu, is a different proposition from an antiparasitic prescribed after a positive stool test. We make no allegation about what CLYR's providers do or do not diagnose, and we found no disease claims on the pages we reviewed. But readers should know that the ivermectin-plus-mebendazole combination is closely associated with unproven online protocols for conditions those drugs do not treat, and a GLP-1 buyer should evaluate that adjacency for themselves.

What Is Not Published

The 503A pharmacy is referenced but not named. No BMI or clinical eligibility criteria. No lab requirements, titration protocol beyond the pricing ladder, or monitoring cadence. No named clinicians, no founding year, and no refund terms — which matters where 8-week cycles and 3-month prepays are billed as single charges of up to $999.